{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Alnylam Pharmaceuticals, Inc."},"Symbol":{"label":"Symbol","value":"ALNY"},"Address":{"label":"Address","value":"675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE, Massachusetts, 2142, United States"},"Phone":{"label":"Phone","value":"+1 617 551-8200"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships."},"CompanyUrl":{"label":"Company Url","value":"https://www.alnylam.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Al Boyle","title":"Chief Technical Operations &amp; Quality Officer"},{"name":"James P. Bilotta","title":"Chief Information Officer &amp; SVP"},{"name":"Kevin Fitzgerald","title":"Chief Scientific Officer &amp; Senior Vice President"},{"name":"Pushkal P. Garg","title":"Chief Medical Officer &amp; EVP-Medical Affairs"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}